Epcoritamab + RSUP2/SUP regimen and responses in patients with high-risk follicular lymphoma, regardless of POD24 status
Merryman, RW Belada, D Sureda, A Leppä, S Vermaat, JSP Holte, H Hutchings, M Lugtenburg, P de Vos, S Abrisqueta, P
Merryman, RW
Belada, D
Sureda, A
Leppä, S
Vermaat, JSP
Holte, H
Hutchings, M
Lugtenburg, P
de Vos, S
Abrisqueta, P
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Merryman RW, Belada D, Sureda A, Leppä S, Vermaat JSP, Holte H, et al. Epcoritamab + R<SUP>2</SUP> Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023 SEP;23:S454-S. PubMed PMID: WOS:001062479600495. English.